10-K: Scientific Industries Reports Fiscal Year 2024 Results: Focus on Bioprocessing Systems

Scientific Industries reports a decrease in net loss for fiscal year 2024, driven by cost reductions in its Bioprocessing Systems operations, while navigating challenges in its Benchtop Laboratory Equipment segment.

Summary

• Scientific Industries, Inc. reported a net loss of $6,445,400 for the year ended December 31, 2024, compared to a net loss of $9,086,500 for the year ended December 31, 2023.
• The decrease in net loss is primarily attributed to reduced operating expenses, particularly in the Bioprocessing Systems segment.
• Net revenues decreased by 3.6% to $10,712,600 in 2024 from $11,111,500 in 2023.
• Bioprocessing Systems revenues increased by approximately $323,700 due to the new DOTS MPS product.
• Benchtop Laboratory Equipment revenues decreased by $722,600, mainly due to lower sales in the Torbal division.
• The gross profit percentage decreased to 44.2% in 2024 from 45.9% in 2023, due to increased costs of materials, labor, and fixed overhead for the Benchtop Laboratory Equipment Operations.
• Research and development expenses decreased by 18.5% to $2,906,100 in 2024, reflecting cost reductions in the Bioprocessing Systems operations.
• The company maintains a full valuation allowance of $9,839,400 against its net deferred tax assets.
• Cash and cash equivalents decreased by $208,200 to $587,900 as of December 31, 2024.
• The company acknowledges substantial doubt about its ability to continue as a going concern and is seeking additional capital resources.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company reduced its net loss, revenue declined, and there are concerns about its ability to continue as a going concern. The company is actively seeking additional capital, which adds uncertainty.

Positives

• The net loss decreased year-over-year, indicating improved financial performance.
• The Bioprocessing Systems segment saw revenue growth with the introduction of a new product.
• The company is actively seeking additional capital to address going concern uncertainties.
• Operating cost reductions mostly in the Bioprocessing Systems Operations segment compared to the prior year period.

Negatives

• The company experienced a decrease in overall net revenues.
• The Benchtop Laboratory Equipment segment saw a decrease in revenue, particularly in the Torbal division.
• The company acknowledges substantial doubt about its ability to continue as a going concern.
• The gross profit percentage decreased due to increased costs of materials, labor, and fixed overhead for the Benchtop Laboratory Equipment Operations.

Risks

• The company has limited financial resources and may need to raise additional funding.
• The commercial success of bioprocessing products depends on market acceptance.
• The company faces intense competition in both the Benchtop Laboratory Equipment and Bioprocessing Systems markets.
• The company is exposed to foreign exchange rate risk.
• The company is heavily dependent on outside suppliers for components.
• The company's ability to compete depends in part on its ability to secure and maintain proprietary rights to its products.
• The company is subject to general economic, political and social factors.

Future Outlook

The Company expects that research and development expenditures in the fiscal year ending December 31, 2025 will continue to be material reflecting continued product development efforts for the Bioprocessing Systems operations.

Management Comments

• Management has developed a strategic plan to secure additional capital resources, which may include capital from management and significant shareholders, third-party equity and/or debt financing, and exploring the sale of certain assets.

Industry Context

The Benchtop Laboratory Equipment industry is a highly competitive mature industry, with constant new entrants into the vortex mixer market, including those offering products imported from China, which the Company is unable to compete with on price.

Comparison to Industry Standards

• The Company's main competition for its Benchtop Laboratory Equipment products derives from private label brand mixers offered by laboratory equipment distributors in the United States and Europe and products exported from China.
• The Company's major competitors for its Genie brand Benchtop Laboratory Equipment are Henry Troemner, Inc., IKA-Werke GmbH & Co. KG, Benchmark Scientific, Inc., and Heidolph Instruments GmbH.
• The Company's main competitors for its Torbal brand products are Ohaus Corporation, A&D Company Ltd., Adam Equipment Co., Ltd., Avery Weigh-Tronix, and Capsa Healthcare for its VIVID brand automated pill counters.
• Direct competitors for the Company's Bioprocessing Systems products are ABER Instruments (United Kingdom) and PreSens GmbH (Germany), indirect (systemic alternatives) competitors include Hamilton Bonaduz AG (Switzerland) and optek-Danulat GmbH (Germany) as well as total solution providers like Sartorius AG (Germany) or Eppendorf SE (Germany).

Related Party Transactions

• Mr. John Nicols, a Director since March 2024, provides consulting services to the Companys Bioprocessing System segment pursuant to consulting agreement which was entered in September 2023.

Stakeholder Impact

• Shareholders face potential dilution from future capital raises.
• Employees may be affected by cost-cutting measures and the company's going concern uncertainties.
• Customers may experience disruptions if the company faces financial difficulties.
• Suppliers may face increased risk of non-payment if the company's financial situation worsens.

Next Steps

• The Company expects that research and development expenditures in the fiscal year ending December 31, 2025 will continue to be material reflecting continued product development efforts for the Bioprocessing Systems operations.
• Management has developed a strategic plan to secure additional capital resources for the Company which may include capital from management and significant shareholders sufficient to meet its operating expenses and third-party equity and/or debt financing and exploring the sale of certain assets.

Key Dates

Keywords

Bioprocessing Systems, Benchtop Laboratory Equipment, Financial Results, Net Loss, Revenue, Scientific Industries, Going Concern, Capital Resources